Transthyretin Amyloidosis (ATTR) Models

Wild Mouse 750
Wild Mouse 750
Human Xenograft Models
Cell Derived Xenograft Models
Autoimmune Disease Models
Systemic Lupus Erythematosus ModelsMultiple Sclerosis ModelsRheumatoid Arthritis ModelsPsoriasis ModelsInflammatory Bowel Disease ModelsAtopic Dermatitis Models Asthma Models
Metabolic Disease Mouse Models
Obesity ModelsDiabetes ModelsNon-alcoholic Steatohepatitis (NASH) ModelsHyperlipidemia ModelsOsteoporosis ModelsHyperuricemia Models
Humanized Immune System Models
huPBMC-NCGhuHSC-NCG-XhuHSC-NCG-hIL15huHSC-NCG
Organs or Tissue Humanized Mouse Models
Wild Mouse 765
Wild Mouse 765
Rare Disease Mouse Models
Progressive Muscular Dystrophy ModelsHemophilia A Models
Neurodegenerative Disease Mouse Models
Alzheimer’s Disease (AD) ModelsParkinson’s Disease (PD) ModelsHuntington's Disease (HD) ModelsAmyotrophic Lateral Sclerosis (ALS) ModelsTransthyretin Amyloidosis (ATTR) Models
Immuno-Oncology Mouse Models
Human Xenograft ModelsHumanized Immune Checkpoint ModelsHumanized Immune System ModelsSpontaneous Tumor Models

Transthyretin amyloidosis (ATTR) is a rare disease caused by the abnormal accumulation of amyloid deposits composed of misfolded transthyretin (TTR) proteins in multiple organs of the body, including the retina, the vitreous, the kidney, and the brain. Transthyretin amyloid polyradiculoneuropathy (ATTR-PN) and transthyretin amyloid cardiomyopathy (ATTR-CM) are prominent subtypes.

GemPharmatech replaces the coding region and regulatory sequences of the murine TTR gene with the corresponding human gene fragments to generate B6-hTTR and B6-hTTR V50M models, which can be used for the study of ATTR  and the in vivo efficacy evaluation of human TTR-targeted gene therapies.


Strain No.
 Strain Name Strain Type Description
T055186 B6-hTTR KI GemPharmatech has established the B6-hTTR model, in which human TTR has been inserted at the region of mouse Ttr. This model can be used to evaluate the efficacy of gene therapies and other drugs in vivo.
T054363 B6-H11-Alb-hTTR V30M KI GemPharmatech established the B6-H11-Alb-hTTR V50M model which expresses human TTR with the point mutation V50M in the liver. This model can be used to evaluate the efficacy of gene therapies and other drugs in vivo.